Non-alcoholic fatty liver disease historical perspective: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
Line 4: Line 4:
   
   
==Overview==
==Overview==
NAFLD/NASH was first described as a medical entity in a 1980. Though its histological capabilities had lengthy been recognized , the time period non-alcoholic steatohepatitis (NASH) became first used by Ludwig et al. as recently as 1980 .Ludwig et al. described ‘‘the pathological and medical features of non-alcoholic disease of the liver related with the pathological features maximum generally seen inside the alcoholic liver disorder itself.  
Non-alcoholic fatty liver disease was first described as a medical entity in a 1980 by Ludwig.  


==Historical Perspective==
==Historical Perspective==


*In 1980, NAFLD was introduced as a new concept in medical history.<ref>Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434-438. PMID 7382552.</ref><ref name="pmid28507929">{{cite journal |vauthors=Vizuete J, Camero A, Malakouti M, Garapati K, Gutierrez J |title=Perspectives on Nonalcoholic Fatty Liver Disease: An Overview of Present and Future Therapies |journal=J Clin Transl Hepatol |volume=5 |issue=1 |pages=67–75 |year=2017 |pmid=28507929 |pmc=5411359 |doi=10.14218/JCTH.2016.00061 |url=}}</ref><ref name="pmid285079292">{{cite journal |vauthors=Vizuete J, Camero A, Malakouti M, Garapati K, Gutierrez J |title=Perspectives on Nonalcoholic Fatty Liver Disease: An Overview of Present and Future Therapies |journal=J Clin Transl Hepatol |volume=5 |issue=1 |pages=67–75 |year=2017 |pmid=28507929 |pmc=5411359 |doi=10.14218/JCTH.2016.00061 |url=}}</ref><ref>Day, CP. Non-alcoholic steatohepatitis (NASH): where are we now and where are we going? Gut. 2002 May; 50(5): 585–588.</ref>
*In 1980, Ludwig was the first physician to describe non-alcoholic fatty liver disease as a separate medical entity from other fatty liver diseases.<ref>Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434-438. PMID 7382552.</ref><ref name="pmid28507929">{{cite journal |vauthors=Vizuete J, Camero A, Malakouti M, Garapati K, Gutierrez J |title=Perspectives on Nonalcoholic Fatty Liver Disease: An Overview of Present and Future Therapies |journal=J Clin Transl Hepatol |volume=5 |issue=1 |pages=67–75 |year=2017 |pmid=28507929 |pmc=5411359 |doi=10.14218/JCTH.2016.00061 |url=}}</ref><ref name="pmid285079292">{{cite journal |vauthors=Vizuete J, Camero A, Malakouti M, Garapati K, Gutierrez J |title=Perspectives on Nonalcoholic Fatty Liver Disease: An Overview of Present and Future Therapies |journal=J Clin Transl Hepatol |volume=5 |issue=1 |pages=67–75 |year=2017 |pmid=28507929 |pmc=5411359 |doi=10.14218/JCTH.2016.00061 |url=}}</ref><ref>Day, CP. Non-alcoholic steatohepatitis (NASH): where are we now and where are we going? Gut. 2002 May; 50(5): 585–588.</ref>
*The association between obesity and NAFLD was made during 1979 by Adler & Schaffner by extending the clinical picture of NASH.
*In 1983, Adler & Schaffner described the association between obesity and non-alcoholic fatty liver disease.
*In an intensive literature seek of 41 papers.published before 1984, reporting on 1515 morbidly overweight sufferers, Andersen & Gluud reported excess fat in 80%,‘‘parenchymal necrosis’’ in 5–63%, fibrosis in 29% and cirrhosis in 3%.<ref name="urlac-els-cdn-com.ezp-prod1.hul.harvard.edu">{{cite web |url=https://ac-els-cdn-com.ezp-prod1.hul.harvard.edu/S0168827898800731/1-s2.0-S0168827898800731-main.pdf?_tid=1d58f5a0-e34a-11e7-894f-00000aab0f26&acdnat=1513529492_9ccae8522acc090e67ec12bca120b87e |title=ac-els-cdn-com.ezp-prod1.hul.harvard.edu |format= |work= |accessdate=}}</ref>
*In 1984, Andersen & Gluud conducted numerous experiments with extensive documentation of the liver biopsies in patients with non-alcoholic fatty liver disease.<ref name="urlac-els-cdn-com.ezp-prod1.hul.harvard.edu">{{cite web |url=https://ac-els-cdn-com.ezp-prod1.hul.harvard.edu/S0168827898800731/1-s2.0-S0168827898800731-main.pdf?_tid=1d58f5a0-e34a-11e7-894f-00000aab0f26&acdnat=1513529492_9ccae8522acc090e67ec12bca120b87e |title=ac-els-cdn-com.ezp-prod1.hul.harvard.edu |format= |work= |accessdate=}}</ref>


==References==
==References==

Revision as of 16:30, 21 December 2017

Non-Alcoholic Fatty Liver Disease Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Non-Alcoholic Fatty Liver Disease from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case studies

Case #1

Non-alcoholic fatty liver disease historical perspective On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Non-alcoholic fatty liver disease historical perspective

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Non-alcoholic fatty liver disease historical perspective

CDC on Non-alcoholic fatty liver disease historical perspective

Non-alcoholic fatty liver disease historical perspective in the news

Blogs on Non-alcoholic fatty liver disease historical perspective

Directions to Hospitals Treating Non-alcoholic fatty liver disease

Risk calculators and risk factors for Non-alcoholic fatty liver disease historical perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Vamsikrishna Gunnam M.B.B.S [2]

Overview

Non-alcoholic fatty liver disease was first described as a medical entity in a 1980 by Ludwig.

Historical Perspective

  • In 1980, Ludwig was the first physician to describe non-alcoholic fatty liver disease as a separate medical entity from other fatty liver diseases.[1][2][3][4]
  • In 1983, Adler & Schaffner described the association between obesity and non-alcoholic fatty liver disease.
  • In 1984, Andersen & Gluud conducted numerous experiments with extensive documentation of the liver biopsies in patients with non-alcoholic fatty liver disease.[5]

References

  1. ↑ Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434-438. PMID 7382552.
  2. ↑ Vizuete J, Camero A, Malakouti M, Garapati K, Gutierrez J (2017). "Perspectives on Nonalcoholic Fatty Liver Disease: An Overview of Present and Future Therapies". J Clin Transl Hepatol. 5 (1): 67–75. doi:10.14218/JCTH.2016.00061. PMC 5411359. PMID 28507929.
  3. ↑ Vizuete J, Camero A, Malakouti M, Garapati K, Gutierrez J (2017). "Perspectives on Nonalcoholic Fatty Liver Disease: An Overview of Present and Future Therapies". J Clin Transl Hepatol. 5 (1): 67–75. doi:10.14218/JCTH.2016.00061. PMC 5411359. PMID 28507929.
  4. ↑ Day, CP. Non-alcoholic steatohepatitis (NASH): where are we now and where are we going? Gut. 2002 May; 50(5): 585–588.
  5. ↑ "ac-els-cdn-com.ezp-prod1.hul.harvard.edu" (PDF).

Template:WS Template:WH

Retrieved from "https://www.wikidoc.org/index.php?title=Non-alcoholic_fatty_liver_disease_historical_perspective&oldid=1423743"